On August 21, 2026, a Phase 3 clinical trial update was recorded for orforglipron, listed under the identifier LY3502970. The study, titled "A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting," is currently in the recruiting stage. This trial is registered as NCT07613307 and falls under Phase 3 of clinical development. The study focuses specifically on participants with type 2 diabetes who observe Ramadan fasting, according to the listed trial title. No results or outcome data have been posted for this study at this time. The current status reflects only that recruitment of participants is underway. Further details regarding trial design, participant numbers, or endpoints are not included in this update. Readers seeking additional information can consult the official trial registry listing for the full protocol and eligibility criteria. This update pertains to glucagon-related compound orforglipron, which remains an approved therapeutic in its current regulatory classification. For more background on this compound, readers can refer to the compound overview.
Orforglipron Phase 3 Trial in Ramadan-Fasting T2D Patients Recruiting
See the full glucagon overview
Source: https://clinicaltrials.gov/study/NCT07613307